# Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

Study · id `cardio:ct-nct07697833` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07697833](<https://clinicaltrials.gov/study/NCT07697833>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07697833

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT07697833. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-15 (anticipated); primary completion 2027-05-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT07697833, source copy `cardio:ctgov-nct07697833-2026-07-13`, retrieved 2026-10-26)
- Planned start: 2026-07-15 (anticipated) (ClinicalTrials.gov record NCT07697833, source copy `cardio:ctgov-nct07697833-2026-07-13`, retrieved 2026-10-26)
- Primary completion: 2027-05-15 (anticipated) (ClinicalTrials.gov record NCT07697833, source copy `cardio:ctgov-nct07697833-2026-07-13`, retrieved 2026-10-26)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07697833, source copy `cardio:ctgov-nct07697833-2026-07-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07697833-2026-07-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
- Acronym: VERICIGUAT
- Condition: Heart Failure With Reduced Ejection Fraction (HFrEF)
- Intervention (Drug): Vericiguat tablet
- Intervention (Drug): Placebo
- Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
- Lead sponsor class: OTHER
- Collaborator: Horizon Pharmaceuticals
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiovascular Diseases, Pakistan (`cardio:org-national-institute-of-cardiovascular-diseases-pakistan`)

## Provenance

Content hash: cc14605c33811dc0d1a24cea0812c0f50f8265cff992ab994e874d269d77190f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
